Clinical Trial Update: Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical study evaluating the combination of ibrutinib and venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Paolo Ghia | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: UNKNOWN